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objectives. To characterize the current economic burden of ventilator-associated pneumonia (VAP) and to determine which services
increase the cost of VAP in North American hospitals.
design and setting. We performed a retrospective, matched cohort analysis of mechanically ventilated patients enrolled in the North
American Silver-Coated Endotracheal Tube (NASCENT) study, a prospective, randomized study conducted from 2002 to 2006 in 54 medical
centers, including 45 teaching institutions (83.3%).
methods. Case patients with microbiologically confirmed VAP ( ) were identified from 542 study participants with claims datanp 30
and were matched by use of a primary diagnostic code, and subsequently by the Acute Physiology and Chronic Health Evaluation II score,
to control patients without VAP ( ). Costs were estimated by applying hospital-specific cost-to-charge ratios based on all-payernp 90
inpatient costs associated with VAP diagnosis-related groups.
results. Median total charges per patient were $198,200 for case patients and $96,540 for matched control patients ( ); corre-P ! .001
sponding median hospital costs were $76,730 for case patients and $41,250 for control patients ( ). After adjusting for diagnosis-Pp .001
related group payments, median losses to hospitals were $32,140 for case patients and $19,360 for control patients ( ). The medianPp .151
duration of intubation was longer for case patients than for control patients (10.1 days vs 4.7 days; ), as were the median durationP ! .001
of intensive care unit stay (18.5 days vs 8.0 days; ) and the median duration of hospitalization (26.5 days vs 14.0 days; ).P ! .001 P ! .001
Examples of services likely to be directly related to VAP and having higher median costs for case patients were hospital care ( ) andP ! .05
respiratory therapy ( ).P ! .05
conclusions. VAP was associated with increased hospital costs, longer duration of hospital stay, and a higher number of hospital
services being affected, which underscores the need for bundled measures to prevent VAP.
trial registration. NASCENT study ClinicalTrials.gov Identifier: NCT00148642.
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The cost of hospitalization has increased by 55% during the
past decade. The most important driver of this increase was
the greater intensity of services provided during hospitali-
zation.1 In the intensive care unit (ICU), where costs are
nearly 3 times those in the general ward,2 mechanical ven-
tilation is an important determinant of excess costs.3 Venti-
lator-associated pneumonia (VAP) increases length of stay in
the ICU and in the hospital, further increasing costs.4-7 Re-
imbursement for cases of VAP paid to hospitals by the Centers
for Medicare and Medicaid Services (CMS) has changed over
time. Before 1983, the CMS reimbursed hospitals for many
extra costs associated with VAP on a fee-for-service basis. In
1983, Medicare implemented the prospective payment system
and reimbursed hospitals a fixed amount determined by the
principal diagnosis on hospital admission. Accordingly, pa-
tients are classified into 1 of approximately 500 diagnosis-
related groups (DRGs) that are expected to utilize similar
hospital resources; patients are classified into a DRG on the
basis of International Classification of Diseases diagnosis, pro-
cedure, age, sex, discharge status, and presence of compli-
cations or comorbidities. With this change, the costs of VAP
incurred by hospitals began to exceed Medicare reimburse-
ment.8 This has future implications, because the incidence of
VAP will increase as a result of the aging population, and
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quality-of-care initiatives may begin to classify VAP as a pre-
ventable complication that is not reimbursable by the CMS.9
Estimates of the economic burden of VAP are quite variable
and ranged from approximately $10,0004-6 to $40,0007 per
patient episode in studies published in the early 2000s. Part
of the variability depends on whether the perspective is that
of the hospital or patient; costs incurred by hospitals4-6 are
lower than charges billed to patients.7 Variability is also at-
tributable to differences in study design and methods, year(s)
when data were collected, hospital location(s), and many
other factors. On the basis of a literature review in which
previously published estimates were converted to 2005 US
dollars, Anderson et al10 recently estimated that the weight-
adjusted mean cost per episode of VAP was $25,000. Data
are limited, however, regarding the impact of VAP on different
hospital services for patients with VAP.
To characterize the current economic burden of VAP on
hospitals and to determine which services increase its cost,
we performed a retrospective cohort analysis of patients en-
rolled in the North American Silver-Coated Endotracheal
Tube (NASCENT) study.11 The NASCENT study was a pro-
spective, randomized study conducted from 2002 to 2006 in
54 medical centers in North America that included 45 teach-
ing institutions (83.3%). Adults requiring mechanical ven-
tilation were randomly assigned to undergo intubation with
a silver-coated tube (Agento I.C.; Bard) or an uncoated tube
(Hi-Lo Endotracheal Tube; Mallinckrodt). Of the 1,509 pa-
tients who were intubated for 24 hours or longer, 93 (6.2%)
developed microbiologically confirmed VAP (ie, 37 [4.8%] of
766 patients using the silver-coated tube and 56 [7.5%] of
743 patients using the uncoated tube [ ]). The pre-Pp .03
liminary results of this cohort analysis of the NASCENT study
have been reported elsewhere.12
methods
To characterize the economic burden of VAP on hospitals
and to determine which services increase its cost, we per-
formed a retrospective matched cohort analysis of patients
enrolled in the NASCENT study.11 Each medical center’s in-
stitutional review board approved the NASCENT study. Writ-
ten informed consent was required and obtained from pa-
tients or their legally authorized representatives.
Patients with medical insurance claim forms and Interna-
tional Classification of Diseases, Ninth Revision, Clinical Modi-
fication procedural codes for mechanical ventilation (codes
96.70–96.72 for mechanical ventilation or codes 96.01–96.05
for nonsurgical intubation of the respiratory tract) were eligible
for inclusion in our retrospective cohort analysis. The diagnosis
of VAP was based on the presence of 104 colony-forming units
or more per milliliter of a pathogen in quantitative bron-
choalveolar lavage fluid obtained from patients intubated for
24 hours or longer. Standard diagnostic criteria13,14 were used
for determining when to obtain samples for culture, namely,
suspicion of VAP or the presence of a new radiographic infil-
trate, plus 2 of the following 3 qualifying clinical signs: fever
or hypothermia, leukocytosis or leukopenia, and/or purulent
tracheal aspirate. Case patients were defined as patients with
microbiologically confirmed VAP; control patients were defined
as patients without microbiologically confirmed VAP. Each case
patient was matched to as many control patients as possible
by primary diagnostic code at admission, receipt of mechanical
ventilation services, and microbiological evidence and was sub-
sequently matched by Acute Physiology and Chronic Health
Evaluation (APACHE) II score at ICU admission.
The primary economic outcome was hospital cost, which
was computed for each patient by linking charge data to a
source of accounting data with the ratio of hospital cost to
patient charge (hereafter the cost-to-charge ratio) for each
hospital and multiplying the hospital-specific cost-to-charge
ratio by the charges for each case. The cost-to-charge ratios
were obtained from CMS historical impact files for the fiscal
years 2003–2005, with the appropriate annual impact file de-
termined by patient discharge date.
Medicare reimbursement was based on DRG payments and
computed for each patient according to the following for-
mula: [(standardized labor share# operating wage index)
(standardized nonlabor share# operating COLA adjustment
for hospitals)]# (1  operating IME  operating DSH ad-
justment factor) # (DRG weight)].15 Standardized labor-re-
lated and nonlabor-related amounts were based on the Fed-
eral Register rules and regulations files for each year. Data
on the operating wage index, the cost-of-living adjustment
(COLA), the indirect medical education (IME) payment, and
the disproportionate share hospital (DSH) adjustment were
obtained from CMS historical impact files for the fiscal years
2003–200516 and were used to adjust payment impacts of
policy changes to DRG payments. A hospital that qualifies
for the DSH adjustment receives higher Medicaid reimburse-
ment than do other hospitals because it treats a dispropor-
tionate share of Medicaid patients. The difference in the num-
ber of nonzero charge events was computed by adding the
number of nonzero charge events within each CMS revenue
category for each patient, which allows for between-group
comparison of the number of events occurring in each service
unit.
Patients’ characteristics and their risk factors for VAP with-
in 30 days of hospital admission were compared between
groups at baseline. Median hospital charges were calculated
for each service category. Costs were estimated by applying
hospital-specific cost-to-charge ratios based on all-payer in-
patient costs. The median duration of intubation and the
median duration of length of stay were calculated for each
cohort. Between-group differences were analyzed by use of
the Wilcoxon-Mann-Whitney test and 1-way analysis of var-
iance for continuous variables and by use of the x2 test for
categorical variables. A P value of less than .05 was considered
to be statistically significant. SAS (SAS Institute) and Stata
(StataCorp) were used for statistical analysis.
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figure 1. Flowchart summarizing enrollment of participants from
the North American Silver-Coated Endotracheal Tube (NASCENT)
study into the present study. APACHE, Acute Physiology and Chronic
Health Evaluation; VAP, ventilator-associated pneumonia.
results
Of the 2,003 patients enrolled in the NASCENT study, 524
(26.2%) had medical insurance claims data.11 Of these 524
patients, 30 (5.7%) had microbiologically confirmed VAP and
were matched by diagnostic code to 90 control patients with-
out VAP (Figure 1). There were no statistically significant dif-
ferences between cohorts in demographic characteristics at
baseline or in risk factors for VAP within 30 days of admission
(Table 1).
Median total hospital charges were $198,200 for case pa-
tients with VAP and $96,540 for control patients without VAP
( ) (Table 2). The average derived cost-to-charge ratiosP ! .001
were similar for case patients and control patients (0.38 vs
0.41; ), resulting in median costs of $76,730 for casePp .203
patients and $41,250 for control patients ( ). AfterPp .001
adjusting for DRG payments, median losses to hospitals were
$32,140 for case patients and $19,360 for control patients
( ). Between-cohort differences remained statisticallyPp .151
significant in the subset of patients who survived, except for
median losses to hospitals ( ).Pp .054
Services with the highest median costs for case patients and
control patients were hospital services ($23,190 vs $11,110;
), pharmacy services ($10,990 vs $6,310; ),Pp .004 Pp .101
laboratory services ($8,512 vs $6,102; ), and respi-Pp .271
ratory therapy ($4,838 vs $2,787; ) (Table 3). Ad-Pp .018
ditional services with higher median costs for case patients
than for control patients included cardiology services (Pp
), operating room services ( ), electrocardiogram.046 P ! .001
services ( ), nuclear medicine services ( ),Pp .017 Pp .042
and recovery room services ( ).Pp .030
The duration of intubation, the duration of ICU stay, and
the duration of hospitalization were longer for case patients
with VAP than they were for control patients without VAP
(Table 4). Between-cohort differences remained statistically
significant in the subset of patients who survived.
discussion
Our study examined the costs associated with patients with
VAP diagnosed on the basis of microbiologic criteria, thereby
avoiding the limitations of clinically diagnosed VAP and help-
ing to delineate excess costs associated with this diagnosis.
Unlike economic studies that focus on major cost determi-
nants, such as length of stay, our approach provides a com-
prehensive analysis of the many different services that con-
tribute to the economic burden of VAP. In addition, our
approach includes both costs based on the cost-to-charge
ratio and Medicare payments based on DRG, allowing cal-
culation of the loss to hospitals for patients with VAP. Most
economic outcomes, including charges, costs, and DRG pay-
ments, were significantly higher for case patients with VAP
than for control patients without VAP. For example, the me-
dian total hospital cost was $35,480 higher for case patients
with VAP than for control patients without VAP. The total
hospital cost was higher for case patients with VAP because
of the increased utilization of services, such as those provided
by the hospital, respiratory department, and other patient-
service units that may contribute indirectly. In addition, the
duration of intubation, the duration of ICU stay, and the
duration of hospitalization were longer for case patients with
VAP than for control patients without VAP.
Other studies4-7 have also reported that costs were signifi-
cantly increased among case patients with VAP, compared
with control patients without VAP. The highest estimate of ap-
proximately $40,000 was based on mean charges of $100,000
for case patients and $60,000 for control patients in a ret-
rospective, matched cohort study of patients hospitalized in
the late 1990s.7 As expected, estimates of costs were lower
than those of charges. For example, mean attributable costs
from the same time period were approximately $10,000 in a
retrospective, matched cohort study4 and $12,000 in a pro-
spective surveillance of patients with costs estimated by use
of a step-down allocation method with multiple linear re-
gression modeling to adjust costs for significant variables.6
Safdar et al5 estimated that the additional costs were ap-
proximately $10,000 on the basis of a quantitative systematic
literature review of studies published from 1991 to 2003 and
on the basis of microcosting that used attributable length of
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table 1. Data on Case Patients with Ventilator-Associated Pneumonia (VAP) and Control Patients without
VAP from the North American Silver-Coated Endotracheal Tube Study, 2002–2006
Characteristic
Case patients
( )np 30
Control patients
( )np 90 P
Male sex 18 (60.0) 43 (47.8) .246
Age .413
Median  SD, years 68.0  15.6 64.5  17.6
Range, years 32–87 24–98
APACHE II score, median (range) 18.0 (11–40) 18.0 (9–40) .925
Risk factors for VAP within 30 days of hospitalization
Functional dependency 7 (23.3) 11 (12.2) .140
Smoking 1 (3.3) 15 (16.7) .063
Impaired sensorium 6 (20.0) 11 (12.2) .290
COPD 3 (10.0) 9 (10.0) 1.99
Long-term steroid use 2 (6.7) 9 (10.0) .584
Emergency surgery or trauma 1 (3.3) 11 (12.2) .160
None 3 (10.0) 18 (20.0) .212
Immunodeficiencya 4 (13.3) 26 (28.9) .088
Use of silver-coated endotracheal tube 16 (53.3) 45 (50.0) .752
Duration of intubationb
Median (range), days 3.7 (1.0–11.4) 4.7 (1–21.8) .332
X4 days 16 (53.3) 36 (40.0) .202c
14 days 14 (46.7) 54 (60.0)
Mortality 5 (16.7) 29 (32.2) .102
note. Data are no. (%) of patients, unless otherwise indicated. APACHE, Acute Physiology and Chronic Health Evaluation;
COPD, chronic obstructive pulmonary disease; SD, standard deviation.
a Defined as 12 weeks of high-dose steroids, presence of human immunodeficiency virus antibody, chemotherapy within 45
days, chemotherapy-induced neutropenia, or immunosuppression for organ transplantation.
b For case patients, we determined the duration of intubation before the onset of VAP.
c Determined from x2 analysis of case patients and control patients for group values.
table 2. Total Hospital Charges and Costs for Case Patients with Ventilator-Associated Pneumonia (VAP) and Control
Patients without VAP from the North American Silver-Coated Endotracheal Tube Study, 2002–2006
Type of patients, charges and costs
Case patients
( )np 30
Control patients
( )np 90 P
All patients
Charges, US$ 198,200 (46,480–579,700) 96,540 (28,920–531,800) !.001
CCR costs, US$ 76,730 (9,713–276,500) 41,250 (8,247–171,600) .001
Average derived CCR 0.38 (0.18–0.54) 0.41 (0.18–0.62) .203
DRG payment, US$ 39,840 (7,151–152,400) 17,840 (4,374–126,200) .001
CCR cost minus DRG payment, US$ 32,140 (34,330 to 191,600) 19,360 (84,860 to 126,300) .151
Survivorsa
Charges, US$ 202,500 (88,180–579,700) 102,300 (31,030–531,800) !.001
CCR costs, US$ 89,550 (33,860–276,500) 43,020 (8,247–171,600) !.001
Average derived CCR 0.38 (0.19–0.54) 0.40 (0.18–0.62) .683
DRG payment, US$ 40,370 (30,000–152,400) 20,510 (4,374–109,400) .004
CCR cost minus DRG payment, US$ 36,920 (10,590 to 191,600) 25,300 (67,490 to 114,000) .054
note. Data are median values (range). CCR, (hospital) cost–to–(patient) charge ratio; DRG, diagnosis-related group.
a There were 25 case patients and 61 control patients who survived.
stay data. More recently, Anderson et al10 estimated that the
weight-adjusted mean costs were $25,000 per episode of VAP
on the basis of a literature review, with costs standardized to
US dollars in 2005. Collectively, findings from previous stud-
ies combined with our findings suggest that the economic
burden of VAP incurred by hospitals is increasing.
Our study updates the body of evidence used to charac-
terize the economic burden of VAP and to determine which
services increase cost; this body of evidence is essential be-
cause CMS reimbursement is based on DRGs, not on each
of the services utilized. In addition, our study provides data
to incentivize the use of preventive strategies in North Amer-
ican hospitals, which will become more important if the CMS
classifies VAP as a nonreimbursable, preventable complica-
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table 3. Hospital Costs for Case Patients with Ventilator-Associated Pneumonia (VAP) and Control
Patients without VAP from the North American Silver-Coated Endotracheal Tube Study, 2002–2006, by
Selected Types of Service
Service (CMS codes)
Median cost (range), US$
P
Case patients
( )np 30
Control patients
( )np 90
Hospital (110–214) 23,190 (2,079–76,070) 11,110 (661–90,330) .004
Pharmacy (250–259) 10,990 (1,376–70,580) 6310 (306–47,220) .101
Laboratory (300–309) 8,512 (1,541–43,340) 6,102 (935–29,500) .271
Respiratory therapy (410–419) 4,838 (0–20,070) 2,787 (0–17,500) .018
Radiology (320–333) 1,531 (287–5,426) 1,179 (188–8,760) 0.146
Cardiology (480–489) 968 (0–14,040) 491 (0–6,029) 0.046
Computed tomography (350–359) 737 (0–9,300) 818 (0–5,644) .167
Operating room (369–371) 717 (0–1,515) 0 (0–1,882) !.001
Blood (380–391) 512 (0–33,430) 385 (0–37,620) .544
Electrocardiogram (730–740) 291 (0–2,016) 126 (0–2,571) .017
Pulmonary diagnostic, unlisted (460) 196 (0–10,770) 0 (0–5,994) .108
Orthopedic diagnostic (920–924) 145 (0–3,177) 0 (0–1,900) .134
Occupational therapy (430–434) 17 (0–2,021) 0 (0–852) .067
Orthopedic rehabilitation (940–949) 0 (0–8,023) 0 (0–1,199) .210
Renal (800–809, 881) 0 (0–5,165) 0 (0–5,707) .668
Ambulatory (490) 0 (0–4,479) 0 (0–1,364) .379
Nuclear medicine (340–343) 0 (0–1,557) 0 (0–1,131) .042
Recovery room (710–719) 0 (0–1,060) 0 (0–1,173) .030
note. CMS, Centers for Medicare and Medicaid Services.
table 4. Duration of Intubation and Length of Stay (LOS) for
Case Patients with Ventilator-Associated Pneumonia (VAP) and
Control Patients without VAP from the North American Silver-
Coated Endotracheal Tube Study, 2002–2006
Type of patient
and variable
Median no.
of days (range)
P
Case
patients
( )np 30
Control
patients
( )np 90
All patients
Intubation durationa 10.1 (3–25) 4.7 (1–22) !.001
VAP onset X4 days 9.1 (3–20)
VAP onset 14 days 12.9 (5–25)
Intensive care unit LOSa 18.5 (5–33) 8.0 (2–33) !.001
VAP onset X4 days 11.5 (5–29)
VAP onset 14 days 23.5 (6–33)
Hospital LOSa 26.5 (5–36) 14.0 (3–50) !.001
VAP onset X4 days 18.5 (5–31)
VAP onset 14 days 31.5 (20–36)
Survivorsb
Intubation duration 10.2 (3–25) 4.8 (1–22) !.001
Intensive care unit LOS 19.0 (5–33) 8.0 (2–33) !.001
Hospital LOS 29.0 (12–36) 16.0 (3–50) !.001
a Duration after VAP onset.
b There were 25 case patients and 61 control patients who survived.
tion. Preventive strategies13,17,18 are often bundled, but imple-
mentation is challenging. Educational interventions have
been shown to be successful at encouraging the use of bun-
dled preventive strategies, and the use of these interventions
has been shown to significantly reduce infection rates in pro-
spective observational studies.19-21 Unfortunately, these ben-
efits tend to subside when there is a lack of continuous edu-
cational reinforcement, and nonadherence is common among
clinicians.22-24 Barriers to adherence include a lack of resources
and an increase in costs.22,24 To maximize the likelihood of suc-
cess, Craven25 advocates a team approach comprising infection
control professionals, infectious disease specialists, critical care
nurses and physicians, respiratory care staff, administrators,
risk management staff, microbiologists, and other stakehold-
ers—all under the direction of an advocate or “champion”
who can market preventive strategies to decision makers re-
sponsible for allocating resources. Our findings provide eco-
nomic support for this multidisciplinary approach, and the
diversity of services impacted by VAP suggests that the list of
team members and services may need to be expanded.
Our study had several limitations, some of which are in-
herent to retrospective cohort analyses. First, our findings were
subject to selection bias due to the retrospective design, but
data were obtained from a large, prospective, multicenter, ran-
domized study.11 To limit bias, we matched case patients to
control patients by primary diagnostic code and APACHE II
score; on the basis of baseline demographic characteristics of
patients and their risk factors for VAP, the cohorts appeared
to be balanced (ie, all P values greater than .05). Our findings
were also subject to selection bias inherent to a randomized,
controlled study performed primarily at teaching hospitals in
the United States, and therefore they may not be generalizable
to nonteaching hospitals or to other countries. In addition, we
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focused on microbiologically documented VAP, as described in
the NASCENT study11; other studies4-7 have reported the eco-
nomic burden of clinically suspected VAP, with and without
microbiologic confirmation, as aggregate findings.
Second, claims data were available for only one-fourth of
patients in the NASCENT study,11 but the 30 case patients
represent the largest economic study of patients with micro-
biologically confirmed VAP. Third, the two-fold increase in
mortality among control patients was unexpected and could
have contributed to between-cohort differences in cost and
length of stay; however, between-cohort differences remained
statistically significant among survivors. Fourth, microcosting
was not feasible for this large multicenter study, so costs were
estimated by summing charges from individual services and
then applying the estimated cost-to-charge ratios on the basis
of matched CMS DRGs. We were not able to obtain service-
specific ratios or patient-specific actual costs but did use hos-
pital-specific ratios and charges for each hospital. Fifth, sam-
ple size precluded statistical evaluation of the onset of VAP
on economic burden, but the higher cost of late-onset, as
opposed to early-onset, VAP has already been reported.6 Sixth,
we performed an unmatched statistical analysis on matched
data, which would tend to increase estimates of standard er-
ror and make it more difficult to detect between-group dif-
ferences. An unmatched approach almost certainly resulted in
a conservative analysis of between-group differences. Seventh,
an estimation of attributable costs, including each of the ser-
vices shown in Table 3, was not feasible, but other studies
have shown that patients with VAP have higher attributable
costs than do patients without VAP.4-6
In conclusion, case patients with microbiologically con-
firmed VAP had a longer duration of mechanical ventilation,
a longer ICU stay, and a longer hospital stay than did con-
trol patients without VAP, which led to significantly higher
charges, hospital costs, and DRG payments. Our findings add
to the current body of literature regarding the economic bur-
den of VAP and the types of services that play a role in
increasing the cost of hospital care for patients with VAP. The
increased total costs and the diversity of resources utilized
underscore the need for bundled measures to prevent VAP.
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